Therapeutic platforms and treatment approaches such as mRNA, cell therapy, gene therapy, RNAi, ADCs, and related innovations.
The radiopharmaceutical landscape in 2026 is defined by the commercial maturity of beta emitters and the rapid clinical ascent of alpha therapies. In the strategic evaluation of Actinium-225 vs Lutetium-177,…
The clinical pipeline for radiopharmaceuticals is undergoing a radical evolution. While the first wave of commercial success relied heavily on beta-emitting isotopes, researchers and biotech innovators are increasingly pivoting toward…
The market for biotherapeutics has experienced a massive surge in transaction activity. Driven by large pharmaceutical companies seeking to replenish oncology pipelines and mid-cap biotechs aiming to establish synergistic combinations,…
The clinical pipeline for antibody-drug conjugates and bispecific antibodies is increasingly defined by the pursuit of validated and novel antigens across solid and hematological malignancies. Recent Targeted Oncology Trials have…
The oncology landscape is undergoing a profound transformation driven by the maturation of highly precise biotherapeutics. As conventional chemotherapies are increasingly superseded by therapies offering enhanced tumor specificity, Targeted Oncology…
The competitive landscape for oncology biotherapeutics is increasingly defined by the diversification of proprietary engineering architectures. While early generations of therapeutics were dominated by a few major players, the current…
BIOSECURE Act was officially signed into law as part of the FY 2026 National Defense Authorization Act (NDAA) on December 18, 2025. This landmark legislation restricts U.S. federal agencies and…
By 2026, biopharma licensing deals involving Chinese originators have surpassed $130 billion in cumulative value. Pfizer and GSK have led the charge, with Chinese assets now comprising 40% of all…
The 2025–2026 metabolic landscape is defined by a massive shift in patient access: the transition from weekly injections to daily oral small molecules. As of March 2026, the oral GLP-1…
By early 2026, Chinese biotech innovation has moved from a “fast-follower” role to a primary global engine for first-in-class oncology assets. Chinese firms now drive 70% of the global ADC…